Candel Therapeutics

Candel Therapeutics

Yahoo Finance • last month

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics Designates Mark Sims as CCO

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes f... Full story

Yahoo Finance • 3 months ago

Candel Therapeutics GAAP EPS of -$0.14 beats by $0.19

* Candel Therapeutics press release [https://seekingalpha.com/pr/20515327-candel-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q1 GAAP EPS of -$0.14 beats b... Full story

Yahoo Finance • 3 months ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, In... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics GAAP EPS of -$0.54

* Candel Therapeutics press release [https://seekingalpha.com/pr/20434729-candel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent] (CADL [https://seekingalpha.com/symbol/CADL]): Q4 GAAP EPS of -$0.54.... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances Proactive uses images sourced from Shutterstock Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibito... Full story

Yahoo Finance • 6 months ago

Candel Therapeutics Prices $100 Mln Shares Offering At $5.45/shr To Advance Aglatimagene;Stock Down

(RTTNews) - Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies, announced the pricing of 18.35 million common shares at $5.45 per share, expecting to ra... Full story

Yahoo Finance • 6 months ago

Candel Therapeutics launches $100M public stock offering; shares down

* Candel Therapeutics (CADL [https://seekingalpha.com/symbol/CADL]) announced [https://seekingalpha.com/pr/20406758-candel-therapeutics-announces-proposed-100-million-public-offering] an underwritten public offering of $100M of its commo... Full story

Yahoo Finance • 9 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 9 months ago

Candel pausing development of CAN-2409 in prostate cancer type

[Prostate cancer with organs and tumor or cancerous cells 3D rendering illustration. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.] libre de droit/iStock via Getty Images * Candel Therapeutics (... Full story

Yahoo Finance • 9 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival... Full story

Yahoo Finance • 9 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 10 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 10 months ago

Candel Therapeutics signs $130M term loan facility with Trinity Capital

* Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]) announced [https://seekingalpha.com/pr/20264571-candel-therapeutics-enters-into-130-million-term-loan-facility-with-trinity-capital-inc]on Tuesday that it has ent... Full story

Yahoo Finance • 10 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC)Provides non-dilutive... Full story

Yahoo Finance • 10 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 10 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story